SCHEMBL3545191

SCHEMBL3545191

O=C(O)CC1(c2cc[c]cc2)CCCC1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.63
TSHR P16473 1/20 0.41
LMNA P02545 3/20 0.41
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
DPP4 P27487 1/20 0.39
EPHX2 P34913 1/20 0.39
ALDH1A1 P00352 1/20 0.38
CYP2C19 P33261 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542558 0.98 HSD11B1 (0.66) HSD11B1TSHRLMNAHSD17B10L3MBTL1
SCHEMBL977926 0.83 HSD11B1 (0.69) HSD11B1TSHRLMNAHSD17B10L3MBTL1
SCHEMBL3545674 0.83 HSD11B1 (0.47) HSD11B1LMNAHSD17B10L3MBTL1SMN1; SMN2
SCHEMBL5365797 0.81 HSD11B1 (0.72) HSD11B1TSHRLMNAHSD17B10L3MBTL1
Hydrochloric Acid SCHEMBL11526870 0.80 HSD11B1 (0.70) HSD11B1TSHRLMNAHSD17B10L3MBTL1
SCHEMBL625584 0.79 HSD11B1 (0.64) HSD11B1TSHRLMNAHSD17B10L3MBTL1
SCHEMBL3538194 0.79 EPHX2 (0.41) HSD11B1TSHRLMNAHSD17B10L3MBTL1
SCHEMBL3548281 0.79 HSD11B1 (0.44) HSD11B1TSHRLMNAHSD17B10L3MBTL1
SCHEMBL3543773 0.79 HSD11B1 (0.44) HSD11B1LMNAHSD17B10L3MBTL1SMN1; SMN2
SCHEMBL4239672 0.79 HSD11B1 (0.68) HSD11B1TSHRLMNAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
CN-101115731-A Oxadiazole derivatives as DGAT inhibitors ASTRAZENECA AB (SE) 2008-01-30 CN claimed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
CN-101115731-A Oxadiazole derivatives as DGAT inhibitors ASTRAZENECA AB (SE) 2008-01-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 HSD11B1 117/4885TSHR 1451/4885LMNA 3296/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 HSD11B1 126/4885TSHR 1169/4885LMNA 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.